芦可替尼联合地西他滨治疗加速期或急变期骨髓增殖性肿瘤的2期研究
这项2期试验纳入25例加速期或急变期骨髓增殖性肿瘤患者,采用芦可替尼联合地西他滨治疗。中位总生存期为9.5个月(95%CI 4.3-12.0),总缓解率为44%(11/25),但缓解与生存改善无关。结论认为该联合方案耐受良好且总生存期有利。
要点
- 芦可替尼联合地西他滨在MPN-AP/BP中耐受良好。
- 中位总生存期9.5个月,总缓解率44%。
- 缓解与生存改善无关联。
核心结论
- 芦可替尼联合地西他滨耐受良好,显示有利的总生存期,可作为高危MPN-AP/BP患者的治疗选择。
研究设计与样本
- 多中心2期试验,纳入25例MPN-AP/BP患者。
- 芦可替尼诱导周期25mg每日两次,后续周期10mg每日两次,联合地西他滨20mg/m2连续5天,28天为一周期。
主要发现
- 研究随访期间19例患者死亡。
- 全部患者中位总生存期为9.5个月(95%CI 4.3-12.0)。
- 总缓解率(完全缓解+血小板不完全恢复+部分缓解)为11/25(44%),缓解与生存改善无关。
临床怎么用
- 该联合方案可作为MPN-AP/BP高危患者的治疗选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms (MPN) that have evolved into accelerated or blast phase disease (MPN-AP/BP) have poor outcomes with limited treatment options and therefore represent an urgent unmet need. We have previously demonstrated in a multicenter, phase 1 trial conducted through the Myeloproliferative Neoplasms Research Consortium that the combination of ruxolitinib and decitabine is safe and tolerable and is associated with a favorable overall survival (OS). In this phase 2 trial, 25 patients with MPN-AP/BP were treated at the recommended phase 2 dose of ruxolitinib 25 mg twice daily for the induction cycle followed by 10 mg twice daily for subsequent cycles in combination with decitabine 20 mg/m2 for 5 consecutive days in a 28-day cycle. Nineteen patients died during the study follow-up. The median OS for all patients on study was 9.5 months (95% confidence interval, 4.3-12.0). Overall response rate (complete remission + incomplete platelet recovery + partial remission) was 11/25 (44%) and response was not associated with improved survival. We conclude that the combination of decitabine and ruxolitinib was well tolerated, demonstrated favorable OS, and represents a therapeutic option for this high-risk patient population. This trial was registered at www.clinicaltrials.gov as #NCT02076191.
引用
- Mascarenhas JO, Rampal RK, Kosiorek HE, et al. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020. PMID: 33104796. doi:10.1182/bloodadvances.2020002119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。